



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

STOCK INFORMATION

CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$8.60
Change (%)	▼ 0.45 (4.97%)
Volume	417,613
52 Week Low	\$8.05
Market Cap	\$498,330,698
Rolling EPS	-5.47
PE Ratio	N/A
Shares Outstanding	57,945,430
Data as of 12/11/17 4:00 p.m. ET	



RECENT NEWS & UPCOMING EVENTS

- 12/01/17
[Coherus BioSciences Management to Present at BMO's Prescriptions for Success Healthcare Conference](#)
- 11/06/17
[Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results](#)
- 11/01/17
[Coherus BioSciences Management to Present at Credit Suisse Scottsdale Healthcare Conference](#)

Date	Title
12/14/17 1:30 p.m. ET	<u>BMO Capital Markets: Prescriptions for Success Healthcare Conference</u>

SEC FILINGS

Filing Date	Form
12/08/17	<u>8-K</u>
12/05/17	<u>8-K</u>
11/06/17	<u>10-Q</u>
11/06/17	<u>8-K</u>

CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.